Gustave Roussy and Protagen AG collaborate to improve the risk profiling of cancer patients undergoing immunotherapy

Villejuif, France and Dortmund, Germany – 10th April, 2018 – Protagen AG and Gustave Roussy have today announced the start of a collaboration to utilize Protagen’s SeroTag® technology to help identify biomarkers that predict and monitor immune-related adverse events (irAEs) in cancer patients treated with checkpoint inhibitors.

Click here to read more.